Participated · Series B · Jan 2024

On February 24, 2021, 依生生物制药有限公司 announced completion of a Series B financing of more than $130 million. The round was co‑led by Oceanpine Capital (海松资本) and OrbiMed (奥博资本). Following the transaction, the company's institutional investor base included Oceanpine, OrbiMed, 斯道资本, F‑Prime Capital, 3W Capital, 高瓴资本, Adjuvant Capital, 和玉资本, AIHC, 益普资本, Superstring Capital and 海通国际. 易凯资本 served as the company's exclusive financial adviser on the deal. The financing expanded the company's investor roster and represents a significant recapitalization event at the B‑round stage. No additional product, operational or use‑of‑proceeds details for the company were provided in the articles.

Participated · Series B · Mar 2021

YishengBio discovers, develops and commercializes biotherapeutics and vaccines using its PIKA® immunomodulating technology platform. Its commercial product, the YSJA™ alum-free lyophilized rabies vaccine, has been launched in China and provided post-exposure protection to over 16 million patients. The company reports more than 60 patents on PIKA technology across over 30 countries and regions. Its clinical pipeline includes candidates such as YS-ON-001 for advanced solid tumors, YS-HBV-001 for hepatitis B, and PIKA YS-SC2-010 for COVID-19, with other candidates in preclinical and discovery stages. YishengBio operates in China, the USA and Singapore and has over 500 employees. The company plans to expand R&D capacity, accelerate commercialization and advance multiple clinical programs, supported by recent financing to build biologics production facilities in China and Singapore.

Led · Equity · Sep 2019

Travel Easy operates a global shopping service platform with a built-in digital tax refund service that matches tourists with shopping options along their travel routes and merchant offers. The platform connects users and merchants before, during and after travel, offering “shopping + tax refund” services and marketing services for merchants intended to increase customer satisfaction and spending. It has partnered with top Chinese travel companies, European department stores, airport retail groups and international brands including Galeries Lafayette, GALERIA Kaufhof, Leica, MCM, Swarovski and Botanicus. The company says it will use the new funding to expand globally. By the end of 2019 Travel Easy plans to launch a pre-order e-commerce service allowing travelers to buy popular products from other European countries not on their trip, removing location restrictions on travel shopping. Travel Easy has set up branches in Frankfurt, Beijing, Wuhan, Prague and Milan.

Participated · Series B · Mar 2018

TCR2 Therapeutics develops a novel class of T cell receptor (TCR)-based cellular therapies that harness the full signaling power of complete TCRs without HLA‑matching. Its proprietary multi-format TRuC™ platform reprograms the natural TCR complex to drive rapid cancer-cell killing with long persistence and low cytokine release. The company is advancing both solid tumor and blood cancer programs from this platform. Proceeds from the recent financing will advance two TRuC™-T cell programs through human proof-of-concept, including lead solid tumor candidate TC-210 targeting mesothelin. TCR2 also plans to expand its platform with dual-target TRuC™, immune cell enhancements and allogeneic technologies. The company is led by CEO Dr. Garry Menzel and is based in Cambridge, MA.

Participated · Series C · Dec 2015

ASLAN Pharmaceuticals is a biopharmaceutical company developing ASLAN003 for autoimmune gastrointestinal and skin diseases and certain skin conditions. The company has closed a secured loan facility with K2 HealthVentures providing up to $45 million of secured debt financing. The facility includes a $20 million initial term loan funded at closing and a further $25 million subject to certain terms and conditions. ASLAN intends to use the proceeds to advance the clinical development of ASLAN003 and for general corporate purposes. The company expects to initiate a Phase 2 clinical trial of ASLAN003 in inflammatory bowel disease in early 2022. The loan provides near-term funding to support those planned clinical activities. ASLAN Pharmaceuticals is a biotech focused on developing immunotherapies and targeted agents for tumour types highly prevalent in Asia. Its pipeline comprises four novel therapeutic agents, with lead drug varlitinib currently in phase 2 trials for cholangiocarcinoma, gastric cancer and breast cancer. Proceeds from the new financing will be used to support clinical development of the pipeline. The company said the financing bolsters its financial position and will accelerate progress across its clinical programme. ASLAN has raised over US$100 million to date, including a US$43 million Series C in December 2015 led by Accuron (a Temasek subsidiary). The announcement was released from Singapore and the company is pursuing growth in Taiwan and the region. Aslan Pharmaceuticals is a Singapore-based biotech focused on developing immunotherapies and targeted agents for tumor types prevalent in Asia. The company maintains a proprietary pipeline of four development-stage candidates addressing multiple indications including gastric and breast cancers and inflammatory diseases. Its most advanced programs are in phase 2: ASLAN001, a pan-HER inhibitor with phase 2 data in gastric cancer and trials in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint target, and cMET. Aslan also operates a global medical device and diagnostics division, Accuron MedTech, led by Abel Ang. The company is led by CEO Dr. Carl Firth and plans to use recent proceeds to accelerate clinical development of ASLAN001, which received Orphan Drug Designation in cholangiocarcinoma from the US FDA.